SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 101 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $504,643 | -30.6% | 34,755 | 0.0% | 0.00% | -20.0% |
| Q2 2023 | $727,422 | +8.9% | 34,755 | +9.9% | 0.01% | 0.0% |
| Q1 2023 | $668,004 | -6.0% | 31,629 | +13.3% | 0.01% | -16.7% |
| Q4 2022 | $710,742 | +9.4% | 27,927 | +3.3% | 0.01% | 0.0% |
| Q3 2022 | $649,507 | +24.9% | 27,029 | 0.0% | 0.01% | +50.0% |
| Q2 2022 | $520,038 | +10.7% | 27,029 | 0.0% | 0.00% | +33.3% |
| Q1 2022 | $469,764 | +25.8% | 27,029 | +58.5% | 0.00% | 0.0% |
| Q4 2021 | $373,290 | +14.5% | 17,053 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $325,883 | +11.3% | 17,053 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $292,800 | +16.8% | 17,053 | +52.1% | 0.00% | +50.0% |
| Q1 2021 | $250,767 | +0.5% | 11,215 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $249,422 | +50.7% | 11,215 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $165,533 | -0.4% | 11,215 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $166,206 | +35.1% | 11,215 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $123,029 | – | 11,215 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |